RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key Stats

• Today's Range: $1.13 to $1.24
• 50-Day Range: $0.90 to $1.22
• 52-Week Range: $0.53 to $2.35
• Volume: 249,694 shs
• Average Volume: 44,845 shs
• Market Capitalization: $29.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.13
• Consensus Rating: Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 52% of companies evaluated by MarketBeat, and ranked 576th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

RenovoRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for RenovoRx are expected to decrease in the coming year, from ($0.41) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 21.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.31% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 21.76%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.27

News Sentiment

RenovoRx has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for RenovoRx this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

Only 3.10% of the stock of RenovoRx is held by institutions.

RNXT Stock Analysis - Frequently Asked Questions

How have RNXT shares performed this year?

RenovoRx's stock was trading at $2.29 at the beginning of the year. Since then, RNXT shares have decreased by 47.2% and is now trading at $1.21.
View the best growth stocks for 2024 here.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

Who are RenovoRx's major shareholders?

Top institutional shareholders of RenovoRx include Geode Capital Management LLC (0.97%). Insiders that own company stock include Shaun Bagai, Ramtin Agah and Angela Nelms.
View institutional ownership trends.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of RenovoRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNXT
• CUSIP: N/A
• CIK: 1574094
• Web: www.renovorx.com
• Phone: 650-284-4433
• Fax: 650-397-4433
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.13
• High Stock Price Target: $8.25
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +406.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,230,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -205.96%
• Return on Assets: -110.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.66
• Quick Ratio: 5.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.28) per share
• Price / Book: -4.32

Miscellaneous

• Outstanding Shares: 24,001,000
• Free Float: 22,297,000
• Market Cap: $29.04 million
• Optionable: Not Optionable
• Beta: 0.99